# Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

> **NCT00694200** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 13 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00694200
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Not reached the statistical hypothesis at the interim analysis
- **Last updated:** 2015-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694200, "Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00694200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*